Parallax Volatility Advisers
CORT icon

Parallax Volatility Advisers’s Corcept Therapeutics CORT Stock Holding History

Parallax Volatility Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,587
Closed -$799K – 3079
2021
Q1 		$799K Buy
+33,587
New +$897K ﹤0.01% 2180
2018
Q4 		– Sell
-61,926
Closed -$868K – 2999
2018
Q3 		$868K Buy
61,926
+25,453
+70% +$356K ﹤0.01% 1315
2018
Q2 		$573K Buy
+36,473
New +$635K ﹤0.01% 1232
2018
Q1 		– Sell
-13,860
Closed -$257K – 2492
2017
Q4 		$250K Buy
+13,860
New +$251K ﹤0.01% 2089

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Parallax Volatility Advisers's CORT Position: Q2 2021 in Review

Parallax Volatility Advisers sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 33,587 shares — an estimated $799K sold.

Parallax Volatility Advisers first reported a position in CORT in Q4 2017 and held it in 4 quarters. The position peaked at $868K in Q3 2018. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

  • Parallax Volatility Advisers reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 33,587 Corcept Therapeutics shares in Q2 2021, an estimated $799K.
  • Parallax Volatility Advisers first reported a position in Corcept Therapeutics in Q4 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Corcept Therapeutics position peaked at $868K in Q3 2018.
  • 199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Parallax Volatility Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.